Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01913535 · ClinicalTrials.gov registry record · Phase 2
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01913535: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01913535 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01913535, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of oral CERC-501 for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
Interventions
- DRUG Placebo
- DRUG CERC-501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-09-12 |
| Est. Completion | 2016-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01913535
The ClinicalTrials.gov registry entry for NCT01913535 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01913535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01913535 about?
NCT01913535 is a clinical study titled "Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression". This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of oral CERC-501 for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
What is the current status of trial NCT01913535?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-09-12. Estimated completion is 2016-01-22.
What interventions are being tested in trial NCT01913535?
The interventions under investigation include: Placebo (DRUG), CERC-501 (DRUG).
Who is sponsoring clinical trial NCT01913535?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.